Director, US HEOR
To develop strategies and identify innovative platforms that enable the collection of Patient Reported Outcomes (PROs) for BMS Oncology portfolio in the Real World
Work with key customers (Payers/Community Oncology Practices/Large IDNs) to partner on Real World Research studies emphasizing EMR & PRO data for IO therapies
Design & execute on Real World HEOR studies with a goal of emphasizing the value of BMS IO therapies to key customers
Work with internal & external stakeholders to ensure key Real World Evidence is being generated to support the value of IO
Collaborate with field HEOR team on PRO studies
Work with internal teams supporting trade and customer management to identify wrap-around data services that drive PRO generation
Present research findings at scientific meetings and contribute to publications
Formal training in HEOR with an emphasis in psychometric theory. Degrees include PharmD, MBA, MS or PhD
Minimum of 5-10 years of HEOR experience working in the Pharmaceutical Industry, Managed Care or Consulting
Ability to design PRO studies with external customers and manage projects in a timely manner
Evaluates, synthesizes, and disseminates multiple sources of real-world data to shape access strategy and demonstrate the value of BMS medicines.
Leverages experience with health technology infrastructure and ePROs to assess data integration and acquisition opportunities for real world research.
Strong understanding of specialty pharmacy care management programs, oncology clinical management, palliative care, quality metrics, and ePROs to identify relevant care impact research and data planning opportunities for value based reimbursement models
Partners with access stakeholders to integrate nuances related to the funding flow, various reimbursement models, and VAP customer segment practices into access strategy and tactics
Identifies data gaps and key unanswered value questions to create customer-centric data plans and FDAMA 114 tools for the therapeutic area.
Develops and aligns HEOR strategy with matrix stakeholders for the therapeutic area